All In MedTech

Device Trial Radar · NCT07444320

Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System

A Multicenter Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System in Patients With Atrial Fibrillation

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Feb 12, 2026

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Mar 2, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, prospective, single-arm, feasibility study to evaluate the safety and effectiveness of the waveforms being delivered using the FARAPULSE PFA System in patients with Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PersAF).

Conditions

  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation

Interventions

  • FARAPULSE™ Pulsed Field Ablation (PFA) SystemDevice

    The FARAWAVE™ PFA Catheter will be used to deliver the investigational waveform(s) for the isolation of pulmonary veins and posterior wall in the treatment of paroxysmal and persistent atrial fibrillation. The FARASTAR™ Generator will be used in conjunction with the FARAWAVE™ PFA Catheter to deliver the investigational waveform(s) for the isolation of pulmonary veins and posterior wall in the treatment of paroxysmal and persistent atrial fibrillation. The FARADRIVE™ Steerable Sheath will be used for percutaneous catheter introduction into the chambers of the heart, including the left side of the heart through the interatrial septum.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Device or procedure-related Composite Adverse Events (CAEs)Time frame: Ablation Procedure Day 0 - Day 7; Day 0 - Day 30; Day 0 - Day 60
  2. Acute Procedural SuccessTime frame: During the Ablation Procedure

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Klinicki Bolnicki Centar Split

    Split, Croatia · Recruiting

  • Na Homolce Hospital

    Prague, Czechia · Recruiting

  • Queen Mary Hospital

    Hong Kong, Hong Kong · Recruiting

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.